GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EQRx Inc (NAS:EQRX) » Definitions » Debt-to-EBITDA

EQRx (EQRX) Debt-to-EBITDA : -0.01 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is EQRx Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

EQRx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $2.06 Mil. EQRx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. EQRx's annualized EBITDA for the quarter that ended in Sep. 2023 was $-171.68 Mil. EQRx's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for EQRx's Debt-to-EBITDA or its related term are showing as below:

EQRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.02   Med: -0.02   Max: -0.01
Current: -0.01

During the past 4 years, the highest Debt-to-EBITDA Ratio of EQRx was -0.01. The lowest was -0.02. And the median was -0.02.

EQRX's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.37 vs EQRX: -0.01

EQRx Debt-to-EBITDA Historical Data

The historical data trend for EQRx's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQRx Debt-to-EBITDA Chart

EQRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
N/A -0.02 -0.02 -0.01

EQRx Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Competitive Comparison of EQRx's Debt-to-EBITDA

For the Biotechnology subindustry, EQRx's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQRx's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EQRx's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where EQRx's Debt-to-EBITDA falls into.



EQRx Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

EQRx's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.37 + 1.461) / -354.942
=-0.01

EQRx's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.06 + 0) / -171.676
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


EQRx  (NAS:EQRX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


EQRx Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of EQRx's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


EQRx (EQRX) Business Description

Traded in Other Exchanges
N/A
Address
50 Hampshire Street, Cambridge, MA, USA, 02139
EQRx Inc is a biotechnology company. the company has more than 10 programs in its pipeline, including clinical, preclinical and drug engineering targets for the treatment of oncology and immune-inflammatory conditions. The program includes Aumolertinib, Lerociclib, Sugemalimab, Nofazinlimab, and others.
Executives
Dina Ciarimboli officer: General Counsel and Secretary EQRX, INC., 50 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Clive Meanwell director THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Andreessen Horowitz Lsv Fund I-b, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Bio Fund Ii-b, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Bio Fund Ii, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Equity Partners Bio Ii, L.l.c. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Equity Partners Lsv Ii, L.l.c. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii-q, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii-b, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Krishna Yeshwant director C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Kathryn E Giusti director 1499 POST ROAD, FAIRFIELD CT 06824
Melanie Nallicheri director, officer: Chief Executive Officer C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Ah Bio Fund Iii, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025

EQRx (EQRX) Headlines

From GuruFocus